Navigation Links
Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
Date:12/5/2007

CAMBRIDGE, Mass, Dec. 5 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. Data from this study are expected to provide substantial evidence for expanding the current product label into adult AML.

"We are very pleased to have reached this milestone and to have done so in a timeframe that we expect will allow us to present preliminary data at ASCO next spring," stated Mark Enyedy, president of Genzyme Oncology. "The completion of patient enrollment in this clinical study is another important step in our plan to broaden the Clolar label to benefit a larger patient population and address multiple lines of adult AML."

Genzyme has held preliminary discussions with the U.S. Food and Drug Administration in advance of submitting a supplemental new drug application (sNDA) for clofarabine as an initial treatment in older adults with AML. The company expects to file this sNDA in the second half of next year.

Significant Unmet Medical Need

The clinical trial, known as CLASSIC II, is designed to address a high unmet medical need among older AML patients who currently have limited treatment options. According to the American Cancer Society, each year approximately 6,500 people over the age of 60 are diagnosed with AML in the U.S. The median survival for those receiving therapy can vary from one to thirteen months, and the five-year survival rate over the past three decades remains at less than 15 percent. Old
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... comparable efficacy and safety for extended release and ... -- New findings from two double-blind ... pramipexole dihydrochloride tablets in an extended release, once-daily ... are being presented today at the American Academy ...
... Cover Therapeutic Delivery Across Blood-Brain BarrierNOVATO, Calif., April ... or the "Company") (OTC Bulletin Board: RPTP) today ... Office ("USPTO") has issued two Notices of Allowance ... titled " Methods of increasing delivery of active ...
Cached Medicine Technology:New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 2Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 3Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 4Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications 5
(Date:4/23/2014)... NY, April 23, 2014Men whose testosterone falls below normal ... to be overweight and have heart disease and type ... identify testosterone-deficient men for further testing and possible treatment ... Men,s Health , a peer-reviewed publication from Mary Ann ... the Journal of Men,s Health website at ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... team of scientists led by a researcher from the ... National University of Singapore has identified the cancer specific ... up the possibility of developing new drugs for the ... , The research group, led by Dr Chan Shing ... the first time that a cancer-specific variant of a ...
(Date:4/23/2014)... the depletion of self-control, according to research published in ... for Psychological Science. , Self-control can be difficult ... on a boring textbook are hard things to do. ... Exerting self-control for a long period seems to "deplete" ... , "It is as if self-control is a limited ...
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... an interesting,snapshot of Minnesotans, changing driving habits, retail ... percent decline compared to sales in July 2007.,According ... motorists,bought 211,982,582 gallons of gasoline in July, compared ... the amount of ethanol-based,E85 sold during the same ...
... medical student in the country. That,s because the three-part ... delivered in a new way: by listening to a ... an Achilles heel in the medical field. , ... test know they don,t have this auditory skill," says Michael ...
... Trevino, master permanent make-up artist and educator joins Nouveau Cosmetique ... advance the education of permanent cosmetic professionals in the US. ... ... August 25, 2008 -- Nouveau Cosmetique USA, Inc., the exclusive ...
... (PTCB) Exhibits at this week,s National Association of Chain Drug ... solutions for enhanced patient safety and the benefits of pharmacy ... ... CA (PRWEB) August 25, 2008 - The https://www.ptcb.org/ ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held September 3-5, 2008 at the,Four ... and Chief Financial Officer of HMS Holdings Corp.,will present ... A live broadcast of the Company,s presentation can ...
... 96 on the, 2008 Inc. 500, with three-year sales growth ... ... Inc. magazine today ranked The,Coding Source No. 96 on its 27th ... list is the most,comprehensive look at the most important segment of the ...
Cached Medicine News:Health News:Listen up! 2Health News:Master Permanent Make-up Artist and Educator Sulema Trevino Joins Nouveau Cosmetique Team 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 3Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 3
Finally, a camera that sees the way you do!,Combined with the MicroLux DVR (Digital Video Recorder), the MicroLux Headlight Camera System gives you an entirely new way to visualize, edit, share and...
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... achieved using an increased tilt angle of ... bed. The patient preparation can be carried ... of an emergency the patient can be ... e.g. resuscitation purposes. The integrated neck support ...
... Magnes 1300 C is ideal for evaluating a ... other parts of the body. Often referred to ... including magnetocardiography, gastrointestinal tract, fetal, spinal cord and ... 1300 C, with its 67 detector coils, covers ...
Medicine Products: